Macitentan denied as non-formulary by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Macitentan as Non-Formulary — And Why You Can Appeal

A non-formulary denial means macitentan is not on Aetna's preferred drug list for your specific plan, or that it is placed at a tier requiring additional authorization. This is a coverage-design decision — not a clinical determination that the drug is inappropriate. Non-formulary denials are routinely appealed through a formulary exception process, which requires demonstrating that formulary alternatives are medically unsuitable for you specifically.

## Why This Denial Is Appealable

Aetna (and most insurers) are required by federal and state law to maintain a formulary exception process. To obtain an exception, your prescriber must document that the formulary alternative(s) are clinically inappropriate for your situation — for example, because you tried them and experienced inadequate response or adverse effects, or because your prescribing physician has a medically documented reason why macitentan is the appropriate choice for your specific presentation.

For PAH in particular, the choice among available ERA medications is often driven by patient-specific clinical factors, dosing considerations, drug interaction profile, and tolerability. Your specialist's clinical judgment about why macitentan is the right agent for you — rather than a formulary alternative — is the core of the exception argument.

## Federal Appeal Framework

• Formulary exception (first step): Request a formulary exception at the same time as, or before, the formal appeal. Provide the prescriber's letter at this stage.
• Internal appeal: If the exception is denied, file a formal internal appeal within the timeframe in the denial letter. Standard: 60 days. Expedited: 72 hours for urgent situations.
• External review (ACA §2719): After exhausting internal appeals, an independent external review by an accredited IRO is available, generally within four months of the final internal denial.
• ERISA §503: Employer-sponsored plans must provide a full-and-fair review of all submitted evidence.

## Documentation to Gather

• Formulary alternative trial history: documentation of any prior trials of Aetna's preferred PAH medications — dates, clinical response, adverse effects, or reason for discontinuation
• Clinical rationale for macitentan specifically: your prescriber's explanation of why the formulary alternatives are medically insufficient and why macitentan is the appropriate agent
• PAH diagnosis and severity documentation: confirming the diagnosis and current disease status
• Prescriber medical-necessity letter: directly addressing Aetna's formulary exception criteria
• Aetna's formulary and exception policy: identify the formulary alternatives listed and address each in your submission

## Criteria-Mapping Structure

Address each formulary alternative Aetna would consider substituting, explaining for each one why it is clinically inappropriate or has already been tried without success. Cite specific chart records for each point. A well-documented formulary exception request often resolves the issue before a formal appeal is needed.